A Phase I Trial of Ibrutinib Plus PD 0332991 (Palbociclib) in Patients With Previously Treated Mantle Cell Lymphoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2017
At a glance
- Drugs Ibrutinib (Primary) ; Palbociclib (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions
- 26 Apr 2017 Planned primary completion date changed from 1 Feb 2017 to 1 May 2017.
- 26 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 06 Dec 2016 Results (n=20) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.